Today, one of the nation’s largest commercial clinical laboratories took a new ovarian cancer screening blood test off the market after the U.S. Food and Drug Administration had issued the company a warning letter on September 29th. The company revealed its decision Friday in a filing with the Securities and Exchange Commission. Some news stories are suggesting that this has raised questions
